Structure-based design and pre-clinical characterization of selective and orally bioavailable Factor XIa inhibitors: Demonstrating the power of an integrated S1 protease family approach.
2020
The serine protease Factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anti-coagulation without an enhanced risk of major bleeds. Several efforts have been descri...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
52
References
6
Citations
NaN
KQI